Core Viewpoint - The Guangdong Provincial People's Congress is focusing on "unbinding" the biopharmaceutical industry to effectively stimulate new productive forces in the sector [2] Group 1: Innovation Assessment Mechanism - The company suggests utilizing big data and AI technologies to explore a market-matching valuation mechanism for assessing innovative pharmaceutical research and development projects [2][4] - A comprehensive evaluation guideline for different stages of biopharmaceutical research projects is recommended, along with a dynamic adjustment mechanism for asset valuation based on emerging technologies and market changes [4] Group 2: Talent Recruitment Mechanism - The company proposes establishing offshore talent recruitment stations in global pharmaceutical hubs to attract top-tier talent, including Nobel laureates and leading scientists [5] - A market-oriented evaluation approach is suggested to give companies greater autonomy in talent assessment, linking individual growth with the long-term development of Guangdong's biopharmaceutical industry [5] Group 3: Error Tolerance Mechanism - The establishment of a systematic error tolerance mechanism at the provincial level is recommended to encourage innovation in the biopharmaceutical sector, which is characterized by high investment, long cycles, and high risks [8][9] - Specific measures include defining tolerable and intolerable errors, setting loss tolerance gradients based on company development stages, and enhancing assessment weights for research investment during strategic transitions [8][9] Group 4: Financial Support for Innovation - The company suggests setting up a provincial innovation risk compensation fund to provide subsidies for failed R&D projects and support banks in offering credit to companies with error tolerance records [9] - A commitment of 10-15 billion yuan for R&D during the 14th Five-Year Plan period has been announced, with over 200 ongoing projects in various therapeutic areas [9]

记者丨唐唯珂 编辑丨季媛媛 中成药淘汰赛序幕拉开！大批中成药将退出市场。 距离2026年7月1日仅剩半年时间，国家药监局《中药注册管理专门规定》第七十五条的落地进入最后窗口期。 这一被业内称为中成药"生死条款"的规定明确，自2023年7月1日施行满三年起，说明书【禁忌】【不良反应】【注意事项】任意一项仍标 注"尚不明确"的中成药，再注册申请将依法不予通过。这意味着，国内现存约5.7万个中成药有效批准文号中，超70%存在安全信息标注问题的 批文将面临淘汰，一场由监管驱动的中药产业深度出清正式进入攻坚阶段。 此次监管新政的核心，是彻底终结中成药说明书长期以来的"尚不明确"时代，倒逼药品持有人补齐上市后安全数据短板。 中国食品药品监管杂志此前研究显示，2018年版《国家基本药物目录》中268个中成药品种的465份说明书里，不良反应、禁忌、药物相互作用 的标注率仅为20.64%、30.1%和1.07%，大量品种依靠模糊表述完成上市后的市场流通。而随着再注册大考临近，这种"模糊免责"的模式已彻 底失去生存空间。 图/图虫 国家药监局的监管动作已提前落地，2025年全年发布多批中成药说明书修订公告，活力苏口服液、固肾生发 ...

记者丨 唐唯珂 编辑丨季媛媛 中成药淘汰赛序幕拉开！大批中成药将退出市场。 距离2026年7月1日仅剩半年时间，国家药监局《中药注册管理专门规定》第七十五条的 落地进入最后窗口期。 这一被业内称为中成药"生死条款"的规定明确，自2023年7月1日施行满三年起，说明书 【禁忌】【不良反应】【注意事项】任意一项仍标注"尚不明确"的中成药，再注册申请 将依法不予通过。这意味着，国内现存约5 . 7万个中成药有效批准文号中，超7 0%存在安 全信息标注问题的批文将面临淘汰，一场由监管驱动的中药产业深度出清正式进入攻坚 阶段。 此次监管新政的核心，是彻底终结中成药说明书长期以来的"尚不明确"时代，倒逼药品 持有人补齐上市后安全数据短板。 中国食品药品监管杂志此前研究显示，2018年版《国家基本药物目录》中2 6 8个中成药品 种的465份说明书里，不良反应、禁忌、药物相互作用的标注率仅为2 0 . 6 4%、3 0 . 1%和 1 . 0 7% ， 大 量 品 种 依 靠 模 糊 表 述 完 成 上 市 后 的 市 场 流 通 。 而 随 着 再 注 册 大 考 临 近 ， 这 种"模糊免责"的模式已彻底失去生存空间。 ...

作为全国老字号嘉年华重点活动、广东"广货行天下"春季行动的重要组成部分，大湾区年味消费季活动 将持续至1月28日。位于陈家祠广场和1906科技园的老字号主题市集，汇集了广州及大湾区其他城市特 色老字号产品。王老吉国际罐、珠江啤酒茶啤新品、双鱼十五运会纪念球等一众广州老字号潮品齐齐亮 相，非遗体验、国潮演出、消费福利轮番上阵，让市民游客沉浸式感受广府老字号的传统底蕴与新潮活 力。 老字号是刻在广州这座千年商都基因里的瑰宝，广州拥有35个中华老字号、82个广东老字号、150个广 州老字号，涵盖食品、餐饮、医药、住宿、文化娱乐、工业制造等行业，构成了岭南商业文化的鲜活版 图。 近年来，广州以政策为支撑、以创新为引擎，为老字号高质量发展保驾护航。2025年出台的《广州老字 号认定管理办法》，将老字号认定移交政府部门规范管理，强化其在商贸流通、消费促进、质量管理等 方面的示范引领作用；将老字号纳入消费新业态新模式新场景试点城市重点支持范畴，对符合条件的项 目给予专项扶持。同时，发挥老字号振兴基金效能，2025年新增投资超1.8亿元，支持惠如楼、白云山 生物、万力轮胎等多个项目发展，建立国资收益后补助激励机制，指导企业" ...

21世纪经济报道记者唐唯珂 距离2026年7月1日仅剩半年时间，国家药监局《中药注册管理专门规定》第七十五条的落地进入最后窗 口期。 这一被业内称为中成药"生死条款"的规定明确，自2023年7月1日施行满三年起，说明书【禁忌】【不良 反应】【注意事项】任意一项仍标注"尚不明确"的中成药，再注册申请将依法不予通过。这意味着，国 内现存约5.7万个中成药有效批准文号中，超70%存在安全信息标注问题的批文将面临淘汰，一场由监 管驱动的中药产业深度出清正式进入攻坚阶段。 此次监管新政的核心，是彻底终结中成药说明书长期以来的"尚不明确"时代，倒逼药品持有人补齐上市 后安全数据短板。 中国食品药品监管杂志此前研究显示，2018年版《国家基本药物目录》中268个中成药品种的465份说明 书里，不良反应、禁忌、药物相互作用的标注率仅为20.64%、30.1%和1.07%，大量品种依靠模糊表述 完成上市后的市场流通。而随着再注册大考临近，这种"模糊免责"的模式已彻底失去生存空间。 国家药监局的监管动作已提前落地，2025年全年发布多批中成药说明书修订公告，活力苏口服液、固肾 生发丸、小活络制剂等多款常用品种均被要求补充三大核心 ...

2026年全国"老字号嘉年华"在广州启动 中新网广州1月27日电 (记者 许青青)记者从26日在广州举行的全国"老字号嘉年华"暨大湾区年味消费季 启动仪式获悉，广州拥有35个中华老字号、82个广东老字号、150个广州老字号，涵盖食品、餐饮、医 药、住宿、文化娱乐、工业制造等行业。 本次活动由商务部联合广东省人民政府举办，以"国货潮品焕彩焕新"为主题，活动将采取"1+4"形式， 以启动仪式为起点，围绕"老字号创意市集""老字号全民共赏""老字号名品博览""老字号匠心出海"四大 主题，组织各地举办35场形式多样、内容丰富的特色活动，扩大优质商品和服务供给，打造多元化、融 合化消费场景，更好满足人民美好生活需要。 编辑：熊思怡 广告等商务合作，请点击这里 本文为转载内容，授权事宜请联系原著作权人 其中，围绕即将到来的马年春节，将集中推出8场全国性主题活动，打造"一站式"购物平台和"打卡 地"消费场景，让消费者在喜庆祥和的节日氛围中享受老字号带来的独特魅力。 中新经纬版权所有，未经书面授权，任何单位及个人不得转载、摘编或以其它方式使用。 关注中新经纬微信公众号(微信搜索"中新经纬"或"jwview")，看更多精彩财经 ...

Core Viewpoint - The A-share pharmaceutical sector has gained renewed investor interest due to the resurgence of COVID-19 cases in India, leading to fluctuations in the Chinese medicine ETF (560080) and notable stock performance among key companies in the sector [1][6]. Group 1: Market Performance - The Chinese medicine ETF (560080) experienced a nearly 2% decline on January 27, following a more than 1.4% increase the previous day, with trading volume surpassing 85 million yuan [1]. - Notable declines were observed in key stocks within the ETF, including Zhongsheng Pharmaceutical down over 7% and Yiling Pharmaceutical down over 5%, with several others also experiencing declines [3]. Group 2: Valuation Insights - The latest price-to-earnings ratio (PE TTM) for the index tracked by the Chinese medicine ETF (560080) is 24.57, indicating that the valuation is below 81.27% of the time since the index was published in May 2015, suggesting a favorable valuation opportunity [4]. Group 3: Company News - Zhongsheng Pharmaceutical announced a projected net profit of 260 million to 310 million yuan for 2025, marking a significant turnaround with an increase of 186.91% to 203.62% year-on-year [7]. - Yiling Pharmaceutical also forecasted a net profit of 1.2 billion to 1.3 billion yuan for 2025, indicating a key operational turning point [7]. - Kangyuan Pharmaceutical received approval for clinical trials of a new traditional Chinese medicine aimed at treating children's adenoid hypertrophy, marking a step forward in innovation [7]. Group 4: Industry Trends - The Chinese traditional medicine market is projected to exceed 700 billion yuan in 2024, driven by stable demand amid an aging population, although pricing volatility has been influenced by inventory adjustments and procurement policies [8]. - The industry is experiencing a consolidation trend, with leading companies capturing over half of the market revenue and profits, while ongoing policy focus on innovation and quality development is reshaping the competitive landscape [8].

Core Viewpoint - The article highlights the evolution of "Guangdong goods" (广货) as a reflection of China's modernization and reform process, showcasing its transformation from traditional manufacturing to intelligent manufacturing and standard output, driven by innovation and strategic investments in emerging industries [1][4]. Group 1: Historical Context and Development - In 1978, Guangdong began its journey in processing and manufacturing, marking the start of "Guangdong goods" as a significant player in the national market [1]. - The "Three Comes and One Supplement" trade model in the 1980s allowed Guangdong to leverage foreign investment and technology, laying a solid foundation for brands like Diamond Fan and Wanbao Refrigerator to expand globally [1][2]. - China's accession to the WTO in 2001 marked a turning point, enabling Guangdong to capitalize on globalization and significantly boost the development of "Guangdong goods" [2]. Group 2: Transition to Intelligent Manufacturing - The evolution of "Guangdong goods" represents a shift from labor-intensive manufacturing to a focus on value chain elevation and intelligent manufacturing [3]. - By 2015, initiatives like "Internet + Intelligent Manufacturing" in cities like Foshan and the integration of robotics in factories exemplified this transition [3]. - The establishment of a robust innovation chain in the Guangdong-Hong Kong-Macao Greater Bay Area has facilitated the transformation of research into commercial products, enhancing Guangdong's competitive edge [3][4]. Group 3: Current Landscape and Future Outlook - Guangdong has increased R&D investments, leading to the emergence of globally competitive enterprises in sectors such as 5G, electric vehicles, and drones, which support the standard output of "Guangdong goods" [4]. - The province's dual advantage in "digital intelligence + mechanical engineering" allows it to meet diverse global demands and market fluctuations effectively [4]. - The ongoing evolution of "Guangdong goods" is characterized by a spirit of innovation and openness, positioning it as a key player in the global market [4].

Core Viewpoint - The launch of the "Intangible Cultural Heritage New Year Celebration: Taste of Chinese New Year" event in Guangzhou aims to promote cultural heritage and stimulate consumption during the Spring Festival [1][3]. Group 1: Event Highlights - The Guangzhou Municipal Bureau of Culture, Radio, Film and Tourism has released the "Top Ten Intangible Cultural Heritage Activities" to guide New Year consumption [3]. - The event includes traditional activities such as flower markets across 11 districts, a fireworks display on New Year's Eve, and two lantern festivals showcasing local culture [4][5]. - A food map featuring intangible cultural heritage cuisine will be introduced, highlighting local food workshops and restaurants, allowing visitors to experience the city's culinary heritage [5]. Group 2: Cultural Engagement - The event will invite nearly 100 tourism bloggers and influencers from 20 countries to experience the festivities and share the warmth of "Guangzhou Year" with the world [7]. - The annual Guangfu Temple Fair will take place around the Lantern Festival, featuring cultural activities that showcase the essence of Guangfu culture [8]. - Various traditional customs and activities will be held during the Spring Festival, including lion dances and cultural performances, providing immersive experiences for visitors [10]. Group 3: Health and Innovation - The event promotes health through the introduction of "Guangzhou Four Seasons Intangible Cultural Heritage Banquet" and health promotion activities at cultural centers [11]. - Over a hundred new intangible cultural heritage products will be launched, reflecting the spirit of the Year of the Horse and aiming to create consumption hotspots [12][13]. - Innovations include collaborations between traditional brands and modern health trends, such as new plant-based beverages and health-focused food products [17][18].

Core Viewpoint - The National Medical Products Administration (NMPA) of China has suspended the import, sale, and use of certain pharmaceutical products from Sun Pharmaceutical Industries Limited and Supriya Lifescience Ltd. due to quality control issues and non-compliance with regulations [1][3][5]. Group 1: Sun Pharmaceutical Industries Limited - Sun Pharmaceutical's Rivastigmine Hydrogen Tartrate Capsules have been suspended due to inadequate risk assessment of batches exceeding standards and deficiencies in quality management during production [1][3]. - The company, established in 1983, was once the highest-valued and largest pharmaceutical firm in India, with Rivastigmine being a first-line treatment for mild to moderate Alzheimer's disease [4]. - The domestic market for Rivastigmine capsules was previously dominated by Novartis until 2018, when Jingxin Pharmaceutical obtained the first generic approval, with the market size estimated at nearly 200 million yuan [4]. Group 2: Supriya Lifescience Ltd. - Supriya Lifescience's Chlorpheniramine Maleate active pharmaceutical ingredient has been suspended due to failure to ensure compliance with production and inspection regulations, as well as inadequate facility management [5][6]. - This is not the first instance of suspension; the same product was previously halted in 2020 for similar quality management issues [2][6]. - Chlorpheniramine Maleate is widely used in over 2,000 cold and allergy medications, and its production has been linked to significant price increases in the past due to market manipulation [7][8].